- Home
- PGY vs XERS Comparison
PGY vs XERS Comparison
Compare PGY & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGY | XERS |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | 518 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.3M | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PGY | XERS |
|---|---|---|
| Price | $13.56 | $6.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $34.50 | $10.83 |
| AVG Volume (30 Days) | ★ 3.6M | 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $14.27 | $34.37 |
| Revenue Next Year | $14.39 | $22.86 |
| P/E Ratio | ★ $13.54 | $615.50 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $10.40 | $4.30 |
| 52 Week High | $44.99 | $10.08 |
Technical Indicators
Market Signals| Indicator | PGY | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 52.70 |
| Support Level | $10.78 | $5.79 |
| Resistance Level | $15.57 | $6.41 |
| Average True Range (ATR) | 0.87 | 0.27 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 18.54 | 33.13 |
Price Performance
Historical ComparisonAbout PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.